Bellicum Pharmaceuticals Inc. (BLCM)

5.18
0.15 2.81
NASDAQ : Health Technology
Prev Close 5.33
Open 5.33
Day Low/High 5.14 / 5.50
52 Wk Low/High 4.96 / 10.66
Volume 213.24K
Avg Volume 388.20K
Exchange NASDAQ
Shares Outstanding 52.80M
Market Cap 292.48M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Noteworthy Wednesday Option Activity: BLCM, WGO, AMCX

Noteworthy Wednesday Option Activity: BLCM, WGO, AMCX

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Bellicum Pharmaceuticals Inc , where a total of 3,837 contracts have traded so far, representing approximately 383,700 underlying shares. That amounts to about 81.3% of BLCM's average daily trading volume over the past month of 471,675 shares.

Bellicum Pharmaceuticals Enters Oversold Territory (BLCM)

Bellicum Pharmaceuticals Enters Oversold Territory (BLCM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

OTC Markets Group Welcomes Blockchain Mining Ltd. To OTCQX

OTC Markets Group Welcomes Blockchain Mining Ltd. To OTCQX

NEW YORK, July 25, 2018 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.

Interesting BLCM Put And Call Options For February 2019

Interesting BLCM Put And Call Options For February 2019

Investors in Bellicum Pharmaceuticals Inc saw new options begin trading this week, for the February 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Bellicum Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For BLCM

Bellicum Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish For BLCM

In trading on Friday, shares of Bellicum Pharmaceuticals Inc crossed above their 200 day moving average of $8.67, changing hands as high as $8.78 per share. Bellicum Pharmaceuticals Inc shares are currently trading up about 5.6% on the day.

Interesting BLCM Call Options For June 15th

Investors in Bellicum Pharmaceuticals Inc saw new options begin trading this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BLCM options chain for the new June 15th contracts and identified the following call contract of particular interest.

5 Stocks Priced Under $10 That You Must Buy

5 Stocks Priced Under $10 That You Must Buy

There are still good bargains to be found in this market, especially among those stocks priced under $10.

First Week of BLCM November 16th Options Trading

First Week of BLCM November 16th Options Trading

Investors in Bellicum Pharmaceuticals Inc saw new options begin trading this week, for the November 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Bellicum Pharmaceuticals, Inc. To Contact The Firm

BELLICUM LEAD PLAINTIFF ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Bellicum Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Bellicum Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bellicum Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - BLCM

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bellicum Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - BLCM

Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bellicum Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - BLCM

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Bellicum Pharmaceuticals, Inc. Of Class Action Lawsuit And Upcoming Deadline - BLCM

Pomerantz LLP announces that a class action lawsuit has been filed against Bellicum Pharmaceuticals, Inc.

Short Interest In Bellicum Pharmaceuticals Jumps 12.7%

Short Interest In Bellicum Pharmaceuticals Jumps 12.7%

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 583,828 share increase in total short interest for Bellicum Pharmaceuticals Inc , to 5,197,737, an increase of 12.65% since 01/31/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc.

First Week of April 20th Options Trading For Bellicum Pharmaceuticals (BLCM)

First Week of April 20th Options Trading For Bellicum Pharmaceuticals (BLCM)

Investors in Bellicum Pharmaceuticals Inc saw new options become available this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BLCM options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

BELLICUM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Bellicum Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bellicum Pharmaceuticals, Inc.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Bellicum Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Texas on behalf of...

BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - BLCM

BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors Of Important Deadline In Class Action - BLCM

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Bellicum Pharmaceuticals, Inc.

Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According To A Recently Filed Class Action

Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According To A Recently Filed Class Action

Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Bellicum Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. - BLCM

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Bellicum Pharmaceuticals, Inc.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

TheStreet Quant Rating: D (Sell)